Investigational Drug Information for Aficamten
✉ Email this page to a colleague
What is the development status for investigational drug Aficamten?
Aficamten is an investigational drug.
There have been 5 clinical trials for Aficamten.
The most recent clinical trial was a Phase 1 trial, which was initiated on August 30th 2023.
The most common disease conditions in clinical trials are Hypertrophy, Cardiomyopathy, Hypertrophic, and Cardiomyopathies. The leading clinical trial sponsors are Cytokinetics, Ji Xing Pharmaceuticals (Shanghai) Co., Ltd., and [disabled in preview].
Summary for Aficamten
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 7 |
| WIPO Patent Applications | 3 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2023-08-30) |
| Vendors | 24 |
Recent Clinical Trials for Aficamten
| Title | Sponsor | Phase |
|---|---|---|
| An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM | Ji Xing Pharmaceuticals (Shanghai) Co., Ltd. | Phase 3 |
| Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM | Cytokinetics | Phase 3 |
| The Purpose of This Study is to Compare the Efficacy and Safety of Aficamten (CK-3773274) Compared With Metoprolol Succinate in Adults With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction | Cytokinetics | Phase 3 |
Clinical Trial Summary for Aficamten
Top disease conditions for Aficamten
Top clinical trial sponsors for Aficamten
US Patents for Aficamten
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
